Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03865446 · ClinicalTrials.gov registry record · Phase 1
Evaluate Severe Hepatic Impairment on Dacomitinib PK
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03865446 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 16 participants.
The verdict
NCT03865446, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a post approval requirement to study the effect of severe hepatic impairment on the pharmacokinetics of dacomitinib.
Interventions
- DRUG Dacomitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-04-05 |
| Est. Completion | 2019-10-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03865446
The ClinicalTrials.gov registry entry for NCT03865446 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dacomitinib is the first listed.
NCT03865446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03865446 about?
NCT03865446 is a clinical study titled "Evaluate Severe Hepatic Impairment on Dacomitinib PK". This is a post approval requirement to study the effect of severe hepatic impairment on the pharmacokinetics of dacomitinib.
What is the current status of trial NCT03865446?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2019-04-05. Estimated completion is 2019-10-24.
What interventions are being tested in trial NCT03865446?
The interventions under investigation include: Dacomitinib (DRUG).
Who is sponsoring clinical trial NCT03865446?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.